LUNG
USDPulmonx Corporation Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.790
High
$1.790
Low
$1.660
Volume
0.89M
Company Fundamentals
Market Cap
69.4M
Industry
Medical devices
Country
United States
Trading Stats
Avg Volume
2.37M
Exchange
NMS
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Oct 31, 2025LUNG (Pulmonx Corporation) Market Analysis: Undervalued MedTech with Mixed Signals
Quick Overview
Pulmonx (LUNG) trades at $2.03 as of October 31, 2025, with a negative P/E ratio (-1.27) and small market cap ($82.6M). Recent analyst upgrades and a management shakeup dominate headlines, while technical indicators show caution. Fundamental scores suggest potential value, but debt and weak equity returns weigh down long-term confidence.
Key News Sentiment
- Analyst Optimism Amid Lower Targets
- Lake Street and D. Boral Capital kept "Buy" ratings but slashed price targets (from $8 → $4 and $16 → $14).
- Why it matters: Analysts see long
Related News
Lake Street Maintains Buy on Pulmonx, Lowers Price Target to $4
Lake Street analyst Frank Takkinen maintains Pulmonx with a Buy and lowers the price target from $8 to $4.
D. Boral Capital Maintains Buy on Pulmonx, Lowers Price Target to $14
D. Boral Capital analyst Jason Kolbert maintains Pulmonx with a Buy and lowers the price target from $16 to $14.
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed
AI PredictionBeta
AI Recommendation
Updated at: Nov 4, 2025, 06:55 PM
61.4% Confidence
Risk & Trading
Entry Point
$1.81
Take Profit
$2.06
Stop Loss
$1.66
Key Factors
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.